These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 6379960)

  • 1. Immunomodulators in the treatment of peritonitis in burned and malnourished animals.
    Waymack JP; Miskell P; Gonce SJ; Alexander JW
    Surgery; 1984 Aug; 96(2):308-14. PubMed ID: 6379960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved survival in severely burned animals using intravenous Corynebacterium parvum vaccine post injury.
    Stinnett JD; Alexander JW; Morris MJ; Dreffer RL; Craycraft TK; Anderson PE; Ogle CK; MacMillan BG
    Surgery; 1981 Feb; 89(2):237-42. PubMed ID: 7455909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of action of two new immunomodulators.
    Waymack JP; Gonce S; Miskell P; Alexander JW
    Arch Surg; 1985 Jan; 120(1):43-8. PubMed ID: 3917663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic immunomodulators for prevention of fatal infections in a burned guinea pig model.
    Stinnett JD; Loose LD; Miskell P; Tenney CL; Gonce SJ; Alexander JW
    Ann Surg; 1983 Jul; 198(1):53-7. PubMed ID: 6407411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymopentin (TP-5) in the treatment of the postburn and postoperative immunodeficiency syndrome.
    Hamilton G; Zöch G; Rath T; Meissl G
    Prog Clin Biol Res; 1989; 308():995-9. PubMed ID: 2528748
    [No Abstract]   [Full Text] [Related]  

  • 6. A prospective study of thymopentin in severely burned patients.
    Waymack JP; Jenkins M; Warden GD; Solomkin J; Law E; Hummel R; Miller A; Alexander JW
    Surg Gynecol Obstet; 1987 May; 164(5):423-30. PubMed ID: 3554564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymopentin increases the survival of mice after allogeneic blood transfusion, bacterial gavage, and burn injury.
    Braga M; Di Francesco A; Gianotti L; Vignali A; Costantini E; Socci C; Fortis C; Paganelli G; Di Carlo V
    Eur J Surg; 1994; 160(6-7):345-50. PubMed ID: 7948352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How do immunomodulators affect host defense in the burn patient?
    Antonacci AC
    J Trauma; 1984 Sep; 24(9 Suppl):S101-18. PubMed ID: 6384529
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunomodulators and wound healing.
    Greenhalgh D; Gamelli RL
    J Trauma; 1987 May; 27(5):510-4. PubMed ID: 3553610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertonic saline enhances host defense to bacterial challenge by augmenting Toll-like receptors.
    Chen LW; Huang HL; Lee IT; Hsu CM; Lu PJ
    Crit Care Med; 2006 Jun; 34(6):1758-68. PubMed ID: 16625117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of thymopentin on postsurgical immune deficiency: a clinical pilot study.
    Faist E; Riedel A; Bolla K
    Int J Clin Pharmacol Res; 1987; 7(1):83-7. PubMed ID: 3294617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of two new immunomodulators on normal and burn injury neutrophils and macrophages.
    Waymack JP; Miskell P; Gonce SJ; Alexander JW
    J Burn Care Rehabil; 1987; 8(1):9-14. PubMed ID: 3553203
    [No Abstract]   [Full Text] [Related]  

  • 13. [Immuno-nutritional recovery of children with severe malnutrition].
    Chevalier P; Sevilla R; Zalles L; Sejas E; Belmonte G; Parent G; Jambon B
    Sante; 1996; 6(4):201-8. PubMed ID: 9026317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Modulating effects of thymopentin on the immune system of severely burned patients].
    Xin G; Zeng Y; Li G
    Zhonghua Shao Shang Za Zhi; 2001 Oct; 17(5):298-300. PubMed ID: 11774820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of macrophage functions by corynebacterium parvum preparations.
    Bonina L; Delfino D; Costa GB; Arena A
    Boll Ist Sieroter Milan; 1989; 68(1):62-6. PubMed ID: 2491287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Burn injury and pulmonary sepsis: development of a clinically relevant model.
    Davis KA; Santaniello JM; He LK; Muthu K; Sen S; Jones SB; Gamelli RL; Shankar R
    J Trauma; 2004 Feb; 56(2):272-8. PubMed ID: 14960967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymopentin in active rheumatoid arthritis. An open, monitored study in 16 patients.
    Franchimont P; Hauwaert C; Bolla K
    Surv Immunol Res; 1985; 4 Suppl 1():81-6. PubMed ID: 3898297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of TP-5 on the production of C3, PGE2, and TXB2 by macrophages obtained from burned guinea pigs.
    Ogle CK; Ogle JD; Keynton L; Nagy H; Alexander JW
    J Burn Care Rehabil; 1989; 10(2):146-50. PubMed ID: 2651450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malnutrition and immunocompetence: increased mortality following an infectious challenge during hyperalimentation.
    Petersen SR; Kudsk KA; Carpenter G; Sheldon GE
    J Trauma; 1981 Jul; 21(7):528-33. PubMed ID: 6788958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thymopentin (TP-5) therapy during lymphadenopathy syndrome (LAS/ARC): preliminary report.
    Costigliola P; Ricchi E; Colangeli V; Pintori C; Boni P; Chiodo F
    J Exp Pathol; 1987; 3(4):705-12. PubMed ID: 3331653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.